{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/goals-outcome-measures/audit-criteria/","result":{"pageContext":{"chapter":{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria","depth":2,"htmlHeader":"<!-- begin field fca5ebd0-8d1f-4c76-a660-61f1d91d8dfe --><h2>Audit criteria</h2><!-- end field fca5ebd0-8d1f-4c76-a660-61f1d91d8dfe -->","summary":null,"htmlStringContent":"<!-- begin item 90634642-ecd1-4960-a51c-a04ecc17b832 --><!-- begin field 995d16da-a863-47ad-914a-7ab380afc763 --><p>The following National Institute for Health and Care Excellence (NICE) audit criteria are relevant for this CKS topic:</p><ul><li>Audit criterion 10. <em>Helicobacter pylori </em>eradication therapy is offered to people who have tested positive for <em>H. pylori</em> and who have peptic ulcer disease.</li><li>Audit criterion 11a. For people with diagnosed peptic ulcer using nonsteroidal anti-inflammatory drugs (NSAIDs), NSAID use is stopped.</li><li>Audit criterion 11b. For people with diagnosed peptic ulcer using NSAIDs, full-dose proton pump inhibitor (PPI) or histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) therapy for 8 weeks is offered.</li><li>Audit criterion 11c. For people with diagnosed peptic ulcer using NSAIDs and in whom <em>H. pylori</em> is present, eradication therapy is offered after PPI or H<sub>2</sub>RA therapy.</li><li>Audit criterion 12. People with gastric ulcer and <em>H. pylori</em> are offered repeat endoscopy 6–8 weeks after beginning treatment.</li><li>Audit criterion 13. People with peptic ulcer and <em>H. pylori</em> are offered re-testing for <em>H. pylori</em> 6–8 weeks after beginning treatment.</li><li>Audit criterion 14. People who have tested negative for <em>H. pylori</em> and are not taking NSAIDs are offered full-dose PPI or H<sub>2</sub>RA for 4–8 weeks.</li><li>Audit criterion 15. People with previous peptic ulcer for whom continuation of NSAID is necessary and are receiving a NSAID are prescribed a PPI.</li><li>Audit criterion 16. In people with an unhealed peptic ulcer, the following are excluded:<ul><li>Non-adherence.</li><li>Malignancy.</li><li>Failure to detect <em>H. pylori</em>.</li><li>Inadvertent NSAID use.</li><li>Other ulcer-inducing medication.</li><li>Rare causes such as Zollinger-Ellison syndrome or Crohn's disease.</li></ul></li><li>Audit criterion 17. If symptoms recur after initial treatment, a PPI is offered to be taken at the lowest dose possible to control symptoms.</li><li>Audit criterion 18. If there is inadequate response to a PPI, H<sub>2</sub>RA therapy is offered.</li></ul><p><em>H. pylori</em> testing</p><ul><li>1. <em>H. pylori</em> is tested for using a carbon-13 urea breath test or a stool antigen test or laboratory-based serology.</li><li>2. Re-testing for <em>H. pylori</em> is performed using a carbon-13 urea breath test.</li><li>3. Office-based serological tests are not used.</li></ul><p>First-line <em>H. pylori</em> treatment</p><ul><li>4. People who test positive for <em>H. pylori</em> are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole.</li></ul></li><li>5. People who are allergic to penicillin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>clarithromycin and</li><li>metronidazole.</li></ul></li><li>6. People who are allergic to penicillin and who have had previous exposure to clarithromycin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li></ul><p>Second-line <em>H. pylori</em> treatment</p><ul><li>7. People who still have symptoms after first-line eradication treatment are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole (whichever was not used first-line).</li></ul></li><li>8. People who have had previous exposure to clarithromycin and metronidazole are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>a quinolone or tetracycline.</li></ul></li><li>9. People who are allergic to penicillin and have not had previous exposure to a quinolone are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and </li><li>metronidazole and </li><li>levofloxacin.</li></ul></li><li>10. People who are allergic to penicillin and who have had previous exposure to a quinolone are offered:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li><li>11. If eradication of <em>H. pylori</em> is not successful with second-line treatment, advice is sought from a gastroenterologist.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/references/\">NICE, 2014</a>]</p><!-- end field 995d16da-a863-47ad-914a-7ab380afc763 --><!-- end item 90634642-ecd1-4960-a51c-a04ecc17b832 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","lastRevised":"Last revised in October 2019","chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","fullItemName":"Management","slug":"management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}